Not Just A Tweak: UK Review Seeks Sea Change In Drug Development
This article was originally published in Scrip
The UK government's Accelerated Access Review is planning to bring big and meaningful changes to the way drugs are developed and brought to UK patients and is not just a tweak to the system. So says, Dr Stuart Dollow, chief executive and founder of Vermilion Life Sciences, who is helping to lead the review.
You may also be interested in...
Earlier dialogues would mean faster access to new medicines.
The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.
The pharmaceutical legislation overhaul offers some solutions to the problem of immature applications.